Related Experiment Video

Updated: Aug 30, 2026

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma
12:24

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma

Published on: September 30, 2021

Treatment considerations in patients with hepatitis C and cirrhosis

E Jenny Heathcote1

  • 1University Health Network, Toronto Western Hospital, Toronto, Ontario, Canada. jenny.heathcote@utoronto.ca

Journal of Clinical Gastroenterology
|October 18, 2003
PubMed

Insights

Antiviral therapy for hepatitis C cirrhosis offers significant benefits, including reduced liver disease progression and cancer risk. Patients with compensated cirrhosis, especially Child Class A, should pursue treatment for better outcomes.

Area of Science:

  • Hepatology
  • Viral Hepatitis
  • Gastroenterology

Background:

  • Cirrhosis due to hepatitis C virus (HCV) infection presents a significant risk of progressive liver disease and mortality.
  • HCV infection is a leading cause of liver cirrhosis and hepatocellular carcinoma worldwide.

Purpose of the Study:

  • To evaluate the efficacy and outcomes of antiviral therapy in patients with hepatitis C-related cirrhosis.
  • To assess the impact of sustained virologic response on liver fibrosis, hepatocellular carcinoma risk, and liver failure in cirrhotic patients.

Main Methods:

  • Treatment with pegylated interferon alfa plus Ribavirin for 48 weeks.
  • Assessment of sustained virologic response (SVR) at 6 months post-treatment.
  • Evaluation of liver histology, fibrosis, and clinical outcomes including hepatocellular carcinoma and liver failure.

Main Results:

  • Sustained virologic response rates of 43% or higher were observed in patients with cirrhosis.
  • Achieving SVR led to reduced liver fibrosis, potential cirrhosis regression, and significantly lower risk of hepatocellular carcinoma and liver failure.
  • Even without SVR, some patients showed histological improvement; compensated cirrhosis patients benefited, while decompensated patients faced safety concerns.

Conclusions:

  • Antiviral therapy, particularly pegylated interferon alfa plus Ribavirin, is highly beneficial for patients with hepatitis C-related cirrhosis.
  • Sustained virologic response is associated with significant long-term clinical benefits, including reduced liver disease progression and cancer development.
  • Treatment is recommended for compensated cirrhotic patients (Child Class A), while those with hepatic decompensation should generally avoid interferon-based therapy due to safety issues.

Related Concept Videos

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
Hepatitis01:25

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...
Cirrhosis I: Introduction01:23

Cirrhosis I: Introduction

Cirrhosis is a chronic, irreversible liver disease characterized by the widespread replacement of healthy liver tissue with fibrotic scar tissue and the formation of regenerative nodules.Etiology of cirrhosisCirrhosis results from sustained liver injury that triggers progressive fibrosis and structural remodeling. The underlying causes are diverse, encompassing common and less frequent clinical conditions. Regardless of the origin, all causes lead to chronic inflammation, hepatocyte loss, and...
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
Esophageal Varices-II: Clinical Features and Management01:28

Esophageal Varices-II: Clinical Features and Management

Esophageal varices often manifest as gastrointestinal bleeding episodes, presenting symptoms like hematemesis (vomiting of blood), hematochezia (passing fresh blood via the rectum), and melena (black, tarry stools). Other signs can include weight loss, anorexia, abdominal discomfort, jaundice, pruritus, altered mental status, and muscle cramps.
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol abuse, or...
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...